<DOC>
	<DOCNO>NCT00911534</DOCNO>
	<brief_summary>The purpose study compare efficacy , safety tolerability rabeprazole extend release ( ER ) 50 mg placebo subject symptomatic gastroesophageal reflux disease ( sGERD ) .</brief_summary>
	<brief_title>Comparing Efficacy , Safety , Tolerability Rabeprazole ER 50 mg With Placebo Subjects With Symptomatic Gastroesophageal Reflux Disease ( sGERD )</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>KEY INCLUSION CRITERIA : Male female , age 18 75 year include study . Females either nonchildbearing potential childbearing potential . Females childbearing potential must negative serum urine pregnancy test prior randomization . Female subject childbearing potential must agree use medically acceptable method contraception start Visit 1 throughout entire study period 1 month last dose study drug . Women use hormonal contraceptive must also use additional approve method contraception start Visit 1 throughout entire study period 1 month last dose study drug . Pregnant lactating female exclude . Subjects must history heartburn , identify main complaint , 6 month longer.Subjects must documentation minimum 5 moderate severe heartburn episode , 3 occur daytime 1 occurs nighttime , last 7 day randomization . Subjects must able read , write , understand language symptom dairy . KEY EXCLUSION CRITERIA : Subjects exclude study find erosive esophagitis esophagogastroduodenoscopy ( EGD ) Screening , current history esophageal motility disorder , current history Barrett 's esophagus , current esophageal stricture esophagitis ( know suspect due etiology GERD infection medication ) , current history ZollingerEllison syndrome acid hypersecretory condition , current gastric duodenal ulcer . Subjects exclude found current history cancer , exception fully excise skin basal cell carcinoma , inflammatory bowel disease , history esophageal , gastric duodenal surgery , except simple closure perforate ulcer . Subjects exclude require daily use nonsteroidal antiinflammatory drug ( NSAIDs ) , oral steroid ( &gt; =20 mg/day prednisone equivalent ) , aspirin ( &gt; 325 mg/day ) . Female subject exclude pregnant , lactating , positive Bhuman gonadotropin test Screening/Baseline . Subjects exclude know human immunodeficiency virus ( HIV ) positive , participate another investigational drug study within 30 day prior screen expect receive investigational drug trial . Subjects unwilling provide inform consent exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Gastroesophageal Reflux Disease</keyword>
	<keyword>GERD</keyword>
</DOC>